Résumé
To establish the efficacy of intracameral injection of moxifloxacin 0.5% [0.5 mg/ml or 500 micro g] ophthalmic solution in patients having routine cataract surgery as prophylaxis to endophthalmitis. Department of Ophthalmology, Sindh Government Qatar Hospital Orangi Town, Karachi. Prospective Case Series. A prospective study was conducted from the period of February 2009 to November 2009 in department of ophthalmology Sindh Government Qatar Hospital Orangi Town, Karachi. Total 530 patients were treated with intracameral injection of 0.5% moxifloxacin solution in 0.1 [500 micro g] ml dose at the conclusion of the surgery with IOL implantation either by doing phacoemulsification or conventional method. Safety parameters included VA, IOP, corneal clarity and edema, aqueous cells and flare were evaluated preoperatively and postoperatively for 3 months in patients who received intracameral injection. Five hundred eyes completed the study while 30 patients were excluded from the study because of poor follow up. Aqueous cells and count on first and third postoperative days were insignificant in all patients who were given intracameral injection of moxifloxacin at the last step of surgery. All eyes had a postoperative best corrected visual acuity of 20/30 or better. No stromal edema was observed. No drug related adverse effects were reported. No case of endophthalmitis was reported during and after the 3 months follows up period. Intracameral injection of moxifloxacin 0.5% [0.5mg/ml or 500 micro g] ophthalmic solution appears to be nontoxic in terms of visual rehabilitation, anterior chamber reaction and corneal edema. It is found very effective for the prophylaxis of endophthalmitis at the conclusion of routine cataract surgery